Trial Profile
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jun 2019
Price :
$35
*
At a glance
- Drugs Candida antigen (Primary)
- Indications Warts
- Focus Therapeutic Use
- Sponsors Nielsen BioSciences
- 12 Apr 2018 Status changed from active, no longer recruiting to completed.
- 15 May 2017 Status changed from recruiting to active, no longer recruiting.
- 02 Feb 2017 Planned End Date changed from 1 Jul 2017 to 1 Jan 2018.